Eric Sagonowsky

Despite Translarna's troubled history at the FDA—and a recent regulatory stumble in Europe—PTC Therapeutics once again hopes to convince U.S. regulators of the value of its Duchenne muscular dystrophy (DMD) therapy.

Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S.

Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to more than 250 workers at the biotech's headquarters in California.

Shortly after Gilead Sciences teamed up with Carlyle's Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway with an asthma rescue inhaler.

A Novartis drug with "pipeline in a pill" potential, according to one analyst group, has delivered on that promise once again.

Less than a year ago, AbbVie's star immunology drug Rinvoq picked up its seventh FDA approval<

During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group.

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.

Targeting a major pharmaceutical market in retinal diseases, EyePoint Pharmaceuticals has revealed that its lead drug candidate failed to meet its endpoint in a phase 2 trial.

In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initiated study in marginal zone lymphoma.